Return to Listing

12 result(s) for Lymphoma

PI Name Protocol # Title
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Brandon Hayes-Lattin IRB00011960 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
Alexey Danilov STUDY00015136 A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies
Stephen Spurgeon STUDY00015255 IIT: A Phase II study of Obinutuzumab (GA-101) in Combination with Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma (ML29535)
Craig Okada STUDY00015315 Phase 1/2 Study of Intratumoral G100 With or Without Pembrolizumab in Patients with Follicular Non-Hodgkin's Lymphoma
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
Andy Chen STUDY00015836 A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia and Advanced Solid Tumors
Alexey Danilov STUDY00016140 A Phase I/II study of Syk inhibitor entospletinib (GS-9973) in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell malignancies
Stephen Spurgeon STUDY00016624 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
Andy Chen STUDY00016830 [NCI CIRB] A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Gary Takahashi STUDY00017126 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080